The results demonstrated the high specificity of NB-Affibody conjugates for HER2-overexpressing breast cancer cells in both in vitro and in vivo experiments, and also verified the high enhancement afforded by NB-Affibody conjugates as a UCA. This evidence concerns the gene ERBB2 and breast cancer.